Jonas Grina

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Eli M. Wallace, James P. Rizzi, Guangzhou Han et al. · Cancer Research · 2016 · 310 citations

Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F. Blake, Michael Burkard, Jocelyn Chan et al. · Journal of Medicinal Chemistry · 2016 · 156 citations · Full text

Erk Kinase Activity, Cellular Pharmacology, Tumor Biology +20

Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (<i>S</i>)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1<i>H</i>-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)

Paul M. Wehn, James P. Rizzi, Darryl D. Dixon et al. · Journal of Medicinal Chemistry · 2018 · 108 citations · Full text

Pyrazolopyridine Inhibitors of B-Raf^V600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors

Steve Wenglowsky, Li Ren, Kateri A. Ahrendt et al. · ACS Medicinal Chemistry Letters · 2011 · 66 citations · Full text

Potent and selective pyrazole-based inhibitors of B-Raf kinase

Joshua D. Hansen, Jonas Grina, Brad Newhouse et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 65 citations · Full text

Medicinal Chemistry, B-raf Kinase, Medicine +6